Towards the Oral Treatment of Ileo-Colonic Inflammatory Bowel Disease with Infliximab Tablets: Development and Validation of the Production Process

Infliximab (IFX) is an intravenously administered monoclonal antibody antagonizing the effects of tumor necrosis factor-alpha (TNF) systemically and is efficacious in the treatment of inflammatory bowel disease (IBD). However, studies suggest that the anti-inflammatory effects result from local immu...

Descripción completa

Detalles Bibliográficos
Autores principales: Gareb, Bahez, Posthumus, Silke, Beugeling, Max, Koopmans, Pauline, Touw, Daan J., Dijkstra, Gerard, Kosterink, Jos G.W., Frijlink, Henderik W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6781063/
https://www.ncbi.nlm.nih.gov/pubmed/31450748
http://dx.doi.org/10.3390/pharmaceutics11090428

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6781063/
https://www.ncbi.nlm.nih.gov/pubmed/31450748
http://dx.doi.org/10.3390/pharmaceutics11090428

Ejemplares similares